Abbott to split into two companies; GSK plans workforce cuts in Canada;

> Abbott ($ABT) says it plans to separate into two publicly traded companies, one in medical products and the other in research-based pharmaceuticals. Release

> GlaxoSmithKline ($GSK) will cut 9% of its workforce in Quebec City, Canada, primarily from a vaccine manufacturing plant. Story

Pharma IQ has come up with a neat graphic of worldwide serialization and traceability mandates. Infographic

> Kenya is scrambling to retrieve thousands of batches of counterfeit anti-retrovirals following reports of irregularities in the appearance and texture of the drugs. Story

> Sentry BioPharma Services in Indianapolis has signed a 5-year contract with the General Service Administration for inclusion on the federal supply schedule, logistics worldwide, for temperature-controlled storage and distribution of vaccines and biopharma products. Release

> Honeywell ($HON) has unveiled Aclar UltRx 6000, a pharmaceutical packaging film that provides a barrier to protect moisture-sensitive medicines in all climates. Item

> Hikma Pharmaceuticals has inaugurated the Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria. Story

> The National Association of State Controlled Substances Authorities (NASCSA) has received a $200,000 grant from Purdue Pharma for the ongoing operation, expansion and awareness of appropriately-designed state prescription drug monitoring programs. Announcement

> Global Logistic Properties is building a dedicated healthcare distribution center in Hangzhou, China. Release

> Movianto Nederland says it is building a 13,000-square-meter GDP-compliant warehouse in Oss, The Netherlands, for storage of deep frozen pharmaceutical products. News

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.